Original ArticlesSurgical treatment of submacular hemorrhage associated with idiopathic polypoidal choroidal vasculopathy☆
Section snippets
Patients and methods
Between December 1995 and March 1998, eight eyes of eight consecutive patients with idiopathic polypoidal choroidal vasculopathy received surgical management of a submacular hemorrhage. The criteria for surgical management of subretinal hemorrhage were the following: (1) thick subretinal hemorrhage involving the center of the macula, (2) no white-yellow clot (organized blood) in the macula, (3) duration of the submacular hemorrhage less than 30 days, (4) no other ocular disease affecting visual
Results
The follow-up period after surgery ranged from 6 to 25 months (mean, 12.6 months). In all five eyes that underwent removal of submacular hemorrhages, most of the subretinal blood was removed at the end of the surgery. On the other hand, in the remaining three eyes that underwent pneumatic displacement of submacular hemorrhages, most of the subretinal blood displaced from the fovea and the subretinal hemorrhage became much thinner in the macula. In four eyes, laser treatment was performed for
Discussion
The natural course of idiopathic polypoidal choroidal vasculopathy is not definitely known because no study of a large series of patients with this disease has been performed. However, the visual prognosis seems to be relatively good. Spaide and associates4 reported that 12 patients had been followed up for a mean of 4.9 years and the final mean visual acuity (20/70) was not significantly different from the initial mean visual acuity (20/60). Moorthy and associates6 also reported that, although
References (23)
- et al.
Multiple recurrent serosanguineous retinal pigment epithelial detachment in black women
Am J Ophthalmol
(1985) - et al.
Idiopathic polypoidal choroidal vasculopathy of the macula
Ophthalmology
(1998) - et al.
Experimental subretinal hemorrhage in rabbits
Am J Ophthalmol
(1982) Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage
Am J Ophthalmol
(1994)- et al.
Submacular hemorrhage removal
Ophthalmology
(1995) - et al.
Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid
Am J Ophthalmol
(1996) - et al.
Management of submacular hemorrhage associated with retinal arterial macroaneurysms
Am J Ophthalmol
(1998) - et al.
Clinicopathologic correlation of surgically excised type 1 and type 2 submacular choroidal neovascularization
Am J Ophthalmol
(1998) - et al.
Idiopathic polypoidal choroidal vasculopathy
Retina
(1990) - et al.
The posterior uveal bleeding syndrome
Retina
(1990)
Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy
Retina
Cited by (77)
Visual prognosis of massive submacular hemorrhage in polypoidal choroidal vasculopathy with or without combination treatment
2016, Journal of the Chinese Medical AssociationCitation Excerpt :Many retrospective case series have evaluated or compared the efficacy and safety of these two surgical procedures. The results showed that both surgical interventions appear to be favorable in management of submacular hemorrhage.2,5,7,16–18 In a literature review, van Zeekes and van Meurs18 even indicated that recent studies tended to use vitrectomy rather than pneumatic displacement.
Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator
2015, American Journal of OphthalmologySurgical management of choroidal neovascularization and subretinal hemorrhage
2012, Retina Fifth EditionSurgical management of sub-retinal haemorrhage secondary to polypoidal choroidal vasculopathy
2011, Journal Francais d'OphtalmologiePolypoidal Choroidal Vasculopathy: A Review
2010, Survey of OphthalmologyCitation Excerpt :Sub-tenon infusion of triamcinolone acetonide may be an optional adjunctive treatmentconsidering the evidence of an inflammatory pathogenic component.32,36,64 Massive subretinal hemorrhage may occur in PCV and has been treated by pars plana vitrectomy.67,85 In 2008, Gomi et al evaluated the efficacy of intravitreal bevacizumab for PCV.18
Systemic Risk Factors for Vitreous Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy
2023, Ophthalmology and Therapy
- ☆
This study was supported in part by the Health Sciences Research Grants from the Ministry of Health and Welfare, Tokyo, Japan.